

PLEASE READ THIS NOTICE CAREFULLY - IT APPLIES TO ALL PERSONS WHO VIEW THIS SITE

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA. THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.

Investors should read the UDRHP-I along with the Draft Abridged Prospectus (as defined below) and seek professional advice before taking any action. J.P. Morgan India Private Limited does not accept any liability whatsoever direct or indirect that may arise from the use of the information contained in the UDRHP-I.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

AGS Health Limited (the “**Company**”) and J.P. Morgan India Private Limited do not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.

The following disclaimer applies to the updated draft red herring prospectus-I dated August 7, 2026 (“**UDRHP-I**”) and the draft abridged prospectus dated August 7, 2026 (“**Draft Abridged Prospectus**”) of the Company filed with the Securities and Exchange Board of India (“**SEBI**”), BSE Limited (“**BSE**”) and National Stock Exchange of India Limited (“**NSE**”, and together with BSE, the “**Stock Exchanges**”) hosted on this website in connection with the proposed initial public offering of equity shares of face value of ₹1 each (“**Equity Shares**”) of the Company comprising a fresh issue aggregating up to ₹18,000 million by the Company (“**Issue**”) and offer for sale aggregating up to ₹30,000 million by BCP Asia II Topco VIII Pte.Ltd (“**Offer for Sale**”, and together with the Issue, “**Offer**”), whereby ICICI Securities Limited, Jefferies India Private Limited, JM Financial Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers (“**BRLMs**”). The UDRHP-I and the Draft Abridged Prospectus has been made available on this website in electronic form solely to comply with Regulation 59C(9) and 59C(9A), respectively of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the UDRHP-I. By accessing the UDRHP-I and the Draft Abridged Prospectus, you agree to follow the following terms and conditions, including any modifications to them from time to time. Access to the UDRHP-I and the Draft Abridged Prospectus does not constitute a recommendation by the Company or any other person to subscribe to the Equity Shares offered in the Offer.

The contents of the UDRHP-I are for your information only and you acknowledge that access to the UDRHP-I and the Draft Abridged Prospectus is intended for use by you only and you agree not to forward the UDRHP-I and the Draft Abridged Prospectus on to any other person, internal or external to your company, in whole or in part, or otherwise provide access via e-mail or otherwise to any person. No part of the contents herein shall be copied or duplicated in any form by any means or redistributed. The UDRHP-I does not amount to, or is intended to be, a prospectus or an offer document, in terms of the Companies Act, 2013, and the SEBI ICDR Regulations, and nothing in the UDRHP-I constitutes an offer or an invitation by or on behalf of either the Company or any of the members of the syndicate to subscribe for or purchase any of the securities described therein. Neither the Company, the BRLMs nor their respective affiliates represent that the contents of the UDRHP-I and the Draft Abridged Prospectus herein are accurate or complete. The information contained in the UDRHP-I and the Draft Abridged Prospectus may not be updated since its original publication date and may not reflect the latest updates. Any forwarding, distribution or reproduction of the contents herein as a whole, or in part is unauthorized.

The information furnished on the following web pages contains information intended only for persons not located in any jurisdiction where the distribution of such information is prohibited or restricted, including the United States, Canada, United Kingdom, Australia and Japan. This information is not to be furnished or made available to any person in the United States, Canada, United Kingdom, Australia or Japan or to any person to whom it is unlawful to furnish or make available such information.

The information on the following web pages is intended solely to provide background information on the Company and does not constitute, or form a part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire, any shares or other securities of the Company in any jurisdiction, including in the United States, and is not for publication, release or distribution in the United

States or to US persons (within the meaning of Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”)). The shares or other securities of the Company have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state of other jurisdiction in the United States, and may not be offered, sold, pledged or otherwise transferred except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

Neither the information on the following web pages nor any copy of any of it may be taken or transmitted into the United States, Canada, United Kingdom, Australia or Japan or distributed, directly or indirectly, in the United States, Canada, United Kingdom, Australia or Japan or to any resident thereof.

The Company and the BRLMs have taken all necessary steps to ensure that the contents of the UDRHP-I and the Draft Abridged Prospectus as appearing on this website are identical to the UDRHP-I and the Draft Abridged Prospectus filed with SEBI and the Stock Exchanges. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently neither the Company, the BRLMs nor any of their respective affiliates accept any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

Potential investors should not rely on the UDRHP-I and the Draft Abridged Prospectus for any investment decision. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the “*Risk Factors*” section of the red herring prospectus, which may be filed with the Registrar of Companies, Tamil Nadu and Andaman and Nicobar Islands, at Chennai (“**RoC**”) in the future. Any decision on whether to invest in the Equity Shares described in the UDRHP-I may only be made after a red herring prospectus has been filed with the RoC and must be made solely on the basis of such red herring prospectus as there may be material changes in the red herring prospectus versus the UDRHP-I.

The link to the audiovisual film of the Company (“**IPO AV**”) will be made available on this website in accordance with the SEBI master circular no. HO/49/14/14(2)2026-CFD-POD2/I/4518/2026 dated February 9, 2026. Such materials are not directed at or intended to be accessed by persons located outside India. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or any advice or recommendation to buy, or sell or transact in any securities of the Company in the United States or in any other jurisdiction, including without limitation, India. The IPO AV provides only the salient features of the Offer and accordingly, potential investors should not rely on the IPO AV. Any decision on whether to invest in the Equity Shares must be made solely on the basis of the red herring prospectus.

Investors are advised not to rely on any other document, content or information provided on the Offer on the internet / online websites/ social media platforms / micro-blogging platforms and by the influencers since the same is not authorized/ approved/ commissioned/ paid by the Company or its Promoters/Directors/Key Managerial Personnel in any manner. Any such posts, including on social media platforms, may be illegal in certain jurisdictions and only certain categories of persons may be authorized to access such information. Such posts, including on social media platforms, do not constitute an offer or solicitation of an offer, or any advice or recommendation to purchase, sell or transact in any of the Company’s securities.

The information is current only as of its date and shall not, under any circumstances, create any implication that the information contained therein is correct as of any time subsequent to the date thereof or that there has been no change in the financial condition or affairs of the Company since such date. This document may be updated from time to time and there is no undertaking by the Company or J.P. Morgan India Private Limited to post any such amendments or supplements on this website.

By clicking on the link below to view the information on the following web pages and other information on this website, you will be deemed to have represented and warranted that:

- (i) you are not currently located in any jurisdiction where distribution of the information on this website is prohibited or restricted, including the United States, Canada, United Kingdom, Australia or Japan;**
- (ii) it is lawful for you to receive a copy of the information contained on this website; and**
- (iii) you have read, understand and agree to comply with all of the restrictions set forth above.**

Please note that forms downloaded and used for subscription to the Offer in contravention of the above will be rejected with no recourse to J.P. Morgan India Private Limited, the Company, or any of their respective affiliates.

[Click here](#) to return to the main menu.

[Click here](#) to continue.